{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:07:30Z","timestamp":1793250450217,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proton pump inhibitors (PPIs) are widely used to treat gastric acid-related disorders. Concerns have been raised about potential fracture risk, especially at the hip, spine and wrist. However, fracture risk at other bone sites has not been as well studied. We investigated the association between PPIs and specific fracture sites using an aggregated knowledge-enhanced database, the Food and Drug Administration Adverse Event Reporting System Data Mining Set (AERS-DM). Proportional reporting ratio (PRR) was used to detect statistically significant associations (signals) between PPIs and fractures. We analyzed both high level terms (HLT) and preferred terms (PT) for fracture sites, defined by MedDRA (Medical Dictionary for Regulatory Activities). Of PPI users reporting fractures, the mean age was 65.3 years and the female to male ratio was 3.4:1. Results revealed signals at multiple HLT and PT fracture sites, consistent for both sexes. These included fracture sites with predominant trabecular bone, not previously reported as being associated with PPIs, such as \u2018rib fractures\u2019, where signals were detected for overall PPIs as well as for each of 5 generic ingredients (insufficient data for dexlansoprazole). Based on data mining from AERS-DM, PPI use appears to be associated with an increased risk for fractures at multiple sites.<\/jats:p>","DOI":"10.1038\/s41598-017-05552-1","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T09:16:23Z","timestamp":1499764583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System"],"prefix":"10.1038","volume":"7","author":[{"given":"Liwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyasee","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"5552_CR1","doi-asserted-by":"publisher","unstructured":"Gomm, W. et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol, doi:10.1001\/jamaneurol.2015.4791 (2016).","DOI":"10.1001\/jamaneurol.2015.4791"},{"key":"5552_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.20452\/pamw.2790","volume":"125","author":"D Ksiadzyna","year":"2015","unstructured":"Ksiadzyna, D., Szelag, A. & Paradowski, L. Overuse of proton pump inhibitors. Polskie Archiwum Medycyny Wewnetrznej-Polish Archives of Internal Medicine 125, 289\u2013298 (2015).","journal-title":"Polskie Archiwum Medycyny Wewnetrznej-Polish Archives of Internal Medicine"},{"key":"5552_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou, B., Huang, Y., Li, H., Sun, W. & Liu, J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis International 27, 339\u2013347, doi:10.1007\/s00198-015-3365-x (2016).","journal-title":"Osteoporosis International"},{"key":"5552_CR4","unstructured":"How Safe Are Popular Reflux Drugs? http:\/\/health.usnews.com\/health-news\/family-health\/bones-joints-and-muscles\/articles\/2009\/11\/04\/how-safe-are-popular-reflux-drugs (accessed 2016)."},{"key":"5552_CR5","unstructured":"McDonagh, M. S., Carson, S. & Thakurta, S. In Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 Drug Class Reviews (2009)."},{"key":"5552_CR6","unstructured":"Top 20 Global Products 2012, IMS Health MIDAS, http:\/\/www.imshealth.com\/deployedfiles\/ims\/Global\/Content\/Corporate\/Press Room\/Top-Line Market Data & Trends\/Top_20_Global_Products_2012_2.pdf (accessed 2016)."},{"key":"5552_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11377-015-0990-z","volume":"10","author":"B Skrzydlo-Radomanska","year":"2015","unstructured":"Skrzydlo-Radomanska, B. & Radwan, P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol 10, 191\u2013196, doi:10.5114\/pg.2015.56109 (2015).","journal-title":"Prz Gastroenterol"},{"key":"5552_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2165\/11599320-000000000-00000","volume":"72","author":"N Vakil","year":"2012","unstructured":"Vakil, N. Prescribing Proton Pump Inhibitors Is it Time To Pause and Rethink? Drugs 72, 437\u2013445 (2012).","journal-title":"Drugs"},{"key":"5552_CR9","first-page":"S174","volume":"21","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard, P., Rejnmark, L. & Mosekilde, L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications, and the risk of fracture. Journal of Bone and Mineral Research 21, S174\u2013S174 (2006).","journal-title":"Journal of Bone and Mineral Research"},{"key":"5552_CR10","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","volume":"296","author":"YX Yang","year":"2006","unstructured":"Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. Jama-Journal of the American Medical Association 296, 2947\u20132953, doi:10.1001\/jama.296.24.2947 (2006).","journal-title":"Jama-Journal of the American Medical Association"},{"key":"5552_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","volume":"24","author":"LA Fraser","year":"2013","unstructured":"Fraser, L. A. et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporosis International 24, 1161\u20131168, doi:10.1007\/s00198-012-2112-9 (2013).","journal-title":"Osteoporosis International"},{"key":"5552_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","volume":"81","author":"MMC van der Hoorn","year":"2015","unstructured":"van der Hoorn, M. M. C., Tett, S. E., de Vries, O. J., Dobson, A. J. & Peeters, G. M. E. E. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 81, 675\u2013682, doi:10.1016\/j.bone.2015.08.024 (2015).","journal-title":"Bone"},{"key":"5552_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"DA Corley","year":"2010","unstructured":"Corley, D. A., Kubo, A., Zhao, W. & Quesenberry, C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients. Gastroenterology 139, 93\u2013101, doi:10.1053\/j.gastro.2010.03.055 (2010).","journal-title":"Gastroenterology"},{"key":"5552_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00198-010-1337-8","volume":"22","author":"S Pouwels","year":"2011","unstructured":"Pouwels, S. et al. Use of proton pump inhibitors and risk of hip\/femur fracture: a population-based case-control study. Osteoporosis International 22, 903\u2013910, doi:10.1007\/s00198-010-1337-8 (2011).","journal-title":"Osteoporosis International"},{"key":"5552_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bone.2012.09.028","volume":"52","author":"C Reyes","year":"2013","unstructured":"Reyes, C. et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 52, 557\u2013561, doi:10.1016\/j.bone.2012.09.028 (2013).","journal-title":"Bone"},{"key":"5552_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12603-016-0679-0","volume":"20","author":"HW Thaler","year":"2016","unstructured":"Thaler, H. W., Sterke, C. S. & van der Cammen, T. J. M. Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers. The journal of nutrition, health & aging 20, 77\u201381 (2016).","journal-title":"The journal of nutrition, health & aging"},{"key":"5552_CR17","doi-asserted-by":"crossref","unstructured":"Targownik, L. E., Goertzen, A. L., Luo, Y. & Leslie, W. D. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. The American Journal of Gastroenterology (2016).","DOI":"10.1038\/ajg.2016.481"},{"key":"5552_CR18","unstructured":"FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm213206.htm (accessed 2016)."},{"key":"5552_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","volume":"124","author":"EW Yu","year":"2011","unstructured":"Yu, E. W., Bauer, S. R., Bain, P. A. & Bauer, D. C. Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International Studies. American Journal of Medicine 124, 519\u2013526, doi:10.1016\/j.amjmed.2011.01.007 (2011).","journal-title":"American Journal of Medicine"},{"key":"5552_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"SL Gray","year":"2010","unstructured":"Gray, S. L. et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative. Archives of internal medicine 170, 765\u2013771 (2010).","journal-title":"Archives of internal medicine"},{"key":"5552_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","volume":"83","author":"WY Elaine","year":"2008","unstructured":"Elaine, W. Y. et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcified tissue international 83, 251\u2013259 (2008).","journal-title":"Calcified tissue international"},{"key":"5552_CR22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","volume":"24","author":"L Fraser","year":"2013","unstructured":"Fraser, L. et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporosis International 24, 1161\u20131168 (2013).","journal-title":"Osteoporosis International"},{"key":"5552_CR23","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/jbmr.2279","volume":"29","author":"JR Lewis","year":"2014","unstructured":"Lewis, J. R. et al. Long-Term Proton Pump Inhibitor Therapy and Falls and Fractures in Elderly Women: A Prospective Cohort Study. Journal of Bone and Mineral Research 29, 2489\u20132497, doi:10.1002\/jbmr.2279 (2014).","journal-title":"Journal of Bone and Mineral Research"},{"key":"5552_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.maturitas.2014.05.019","volume":"78","author":"LM Moberg","year":"2014","unstructured":"Moberg, L. M., Nilsson, P. M., Samsioe, G. & Borgfeldt, C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 78, 310\u2013315 (2014).","journal-title":"Maturitas"},{"key":"5552_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-014-9855-6","volume":"94","author":"J Ding","year":"2014","unstructured":"Ding, J., Heller, D. A., Ahern, F. M. & Brown, T. V. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcified tissue international 94, 597\u2013607 (2014).","journal-title":"Calcified tissue international"},{"key":"5552_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1007\/s10620-012-2185-5","volume":"57","author":"M Mello","year":"2012","unstructured":"Mello, M. et al. Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Digestive diseases and sciences 57, 2416\u20132422 (2012).","journal-title":"Digestive diseases and sciences"},{"key":"5552_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety 11, 3\u201310, doi:10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"5552_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"5552_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"J Almenoff","year":"2007","unstructured":"Almenoff, J. et al. Novel statistical tools for monitoring the safety of marketed drugs. Clinical Pharmacology & Therapeutics 82, 157\u2013166 (2007).","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"5552_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiology and Drug Safety 13, 519\u2013523, doi:10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"5552_CR31","doi-asserted-by":"crossref","unstructured":"Wang, L. W., Jiang, G. Q., Li, D. C. & Liu, H. F. Standardizing adverse drug event reporting data. Journal of Biomedical Semantics 5 (2014).","DOI":"10.1186\/2041-1480-5-36"},{"key":"5552_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi, E., Raschi, E., Moretti, U. & De Ponti, F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiology and Drug Safety 18, 512\u2013518, doi:10.1002\/pds.1746 (2009).","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"5552_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.7150\/ijms.8.332","volume":"8","author":"T Sakaeda","year":"2011","unstructured":"Sakaeda, T. et al. Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS. International Journal of Medical Sciences 8, 332\u2013338 (2011).","journal-title":"International Journal of Medical Sciences"},{"key":"5552_CR34","doi-asserted-by":"crossref","unstructured":"Jiang, G. Q., Liu, H. F., Solbrig, H. R. & Chute, C. G. Mining severe drug-drug interaction adverse events using Semantic Web technologies: a case study. Biodata Mining 8 (2015).","DOI":"10.1186\/s13040-015-0044-6"},{"key":"5552_CR35","doi-asserted-by":"publisher","first-page":"24955","DOI":"10.1038\/srep24955","volume":"6","author":"Y Yu","year":"2016","unstructured":"Yu, Y. et al. Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events. Sci Rep 6, 24955, doi:10.1038\/srep24955 (2016).","journal-title":"Sci Rep"},{"key":"5552_CR36","doi-asserted-by":"crossref","unstructured":"Jiang, G., Wang, L., Liu, H., Solbrig, H. R. & Chute, C. G. Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies. MedInfo 2013, 496\u2013500 (2013).","DOI":"10.3233\/978-1-61499-289-9-496"},{"key":"5552_CR37","doi-asserted-by":"crossref","unstructured":"Wang, L. & Liu, H. In Bioinformatics and Biomedicine (BIBM), 2013 IEEE International Conference on. 46\u201352 (IEEE).","DOI":"10.1109\/BIBM.2013.6732599"},{"key":"5552_CR38","unstructured":"Pathologic Fracture, http:\/\/orthopedics.about.com\/cs\/brokenbones\/g\/pathologic.htm (accessed 2016)."},{"key":"5552_CR39","unstructured":"Pathological Fracture, http:\/\/www.ivyroses.com\/HumanBody\/Skeletal\/Fractures\/Pathological-Fracture.php (accessed 2016)."},{"key":"5552_CR40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","volume":"118","author":"MB O\u2019Connell","year":"2005","unstructured":"O\u2019Connell, M. B., Madden, D. M., Murray, A. M., Heaney, R. P. & Kerzner, L. J. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. American Journal of Medicine 118, 778\u2013781, doi:10.1016\/j.amjmed.2005.02.007 (2005).","journal-title":"American Journal of Medicine"},{"key":"5552_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1742-1241.2008.01883.x","volume":"63","author":"A Kirkpantur","year":"2009","unstructured":"Kirkpantur, A., Altun, B., Arici, M. & Turgan, C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. International journal of clinical practice 63, 261\u2013268 (2009).","journal-title":"International journal of clinical practice"},{"key":"5552_CR42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","volume":"138","author":"LE Targownik","year":"2010","unstructured":"Targownik, L. E., Lix, L. M., Leung, S. & Leslie, W. D. Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology 138, 896\u2013904, doi:10.1053\/j.gastro.2009.11.014 (2010).","journal-title":"Gastroenterology"},{"key":"5552_CR43","doi-asserted-by":"crossref","unstructured":"Amoako, A. O., Jafilan, L., Nasiri, P. & Pujalte, G. G. Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Curr Rheumatol Rev (2016).","DOI":"10.2174\/1573397112666160331143135"},{"key":"5552_CR44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/ajg.2012.200","volume":"107","author":"LE Targownik","year":"2012","unstructured":"Targownik, L. E. et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). The American journal of gastroenterology 107, 1361\u20131369 (2012).","journal-title":"The American journal of gastroenterology"},{"key":"5552_CR45","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1111\/febs.12478","volume":"280","author":"J Costa-Rodrigues","year":"2013","unstructured":"Costa-Rodrigues, J., Reis, S., Teixeira, S., Lopes, S. & Fernandes, M. H. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. Febs Journal 280, 5052\u20135064, doi:10.1111\/febs.12478 (2013).","journal-title":"Febs Journal"},{"key":"5552_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00223-012-9601-x","volume":"90","author":"T Histing","year":"2012","unstructured":"Histing, T. et al. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int 90, 507\u2013514, doi:10.1007\/s00223-012-9601-x (2012).","journal-title":"Calcif Tissue Int"},{"key":"5552_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bone.2013.08.013","volume":"57","author":"B Abrahamsen","year":"2013","unstructured":"Abrahamsen, B. & Vestergaard, P. Proton pump inhibitor use and fracture risk - effect modification by histamine H-1 receptor blockade. Observational case-control study using National Prescription Data. Bone 57, 269\u2013271, doi:10.1016\/j.bone.2013.08.013 (2013).","journal-title":"Bone"},{"key":"5552_CR48","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12020-015-0576-z","volume":"49","author":"AN Lau","year":"2015","unstructured":"Lau, A. N., Tomizza, M., Wong-Pack, M., Papaioannou, A. & Adachi, J. D. The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 49, 606\u2013610 (2015).","journal-title":"Endocrine"},{"key":"5552_CR49","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/jgs.13661","volume":"63","author":"AM Hinson","year":"2015","unstructured":"Hinson, A. M. et al. Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults. Journal of the American Geriatrics Society 63, 2070\u20132073, doi:10.1111\/jgs.13661 (2015).","journal-title":"Journal of the American Geriatrics Society"},{"key":"5552_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.bone.2013.09.014","volume":"57","author":"M Maggio","year":"2013","unstructured":"Maggio, M. et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57, 437\u2013442 (2013).","journal-title":"Bone"},{"key":"5552_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","volume":"84","author":"C Roux","year":"2009","unstructured":"Roux, C. et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcified tissue international 84, 13\u201319 (2009).","journal-title":"Calcified tissue international"},{"key":"5552_CR52","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1136\/bmj.e372","volume":"344","author":"H Khalili","year":"2012","unstructured":"Khalili, H. et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMj 344, e372 (2012).","journal-title":"BMj"},{"key":"5552_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12603-016-0679-0","volume":"20","author":"H Thaler","year":"2016","unstructured":"Thaler, H., Sterke, C. & Van Der Cammen, T. J. Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: A study of medication use in older fallers. The journal of nutrition, health & aging 20, 77\u201381 (2016).","journal-title":"The journal of nutrition, health & aging"},{"key":"5552_CR54","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s00198-015-3168-0","volume":"26","author":"D Freedberg","year":"2015","unstructured":"Freedberg, D. et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporosis International 26, 2501\u20132507 (2015).","journal-title":"Osteoporosis International"},{"key":"5552_CR55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jbmr.2072","volume":"29","author":"S Amin","year":"2014","unstructured":"Amin, S., Achenbach, S. J., Atkinson, E. J., Khosla, S. & Melton, L. J. Trends in Fracture Incidence: A Population\u2010Based Study Over 20 Years. Journal of Bone and Mineral Research 29, 581\u2013589 (2014).","journal-title":"Journal of Bone and Mineral Research"},{"key":"5552_CR56","unstructured":"Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS), http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm (accessed 2016)."},{"key":"5552_CR57","unstructured":"FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files, http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm (accessed 2016)."},{"key":"5552_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1197\/jamia.M3378","volume":"17","author":"H Xu","year":"2010","unstructured":"Xu, H. et al. MedEx: a medication information extraction system for clinical narratives. Journal of the American Medical Informatics Association 17, 19\u201324 (2010).","journal-title":"Journal of the American Medical Informatics Association"},{"key":"5552_CR59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","volume":"18","author":"SJ Nelson","year":"2011","unstructured":"Nelson, S. J., Zeng, K., Kilbourne, J., Powell, T. & Moore, R. Normalized names for clinical drugs: RxNorm at 6 years. Journal of the American Medical Informatics Association 18, 441\u2013448 (2011).","journal-title":"Journal of the American Medical Informatics Association"},{"key":"5552_CR60","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.ijmedinf.2009.01.001","volume":"78","author":"RK Pearson","year":"2009","unstructured":"Pearson, R. K. et al. Influence of the MedDRA\u00ae hierarchy on pharmacovigilance data mining results. International journal of medical informatics 78, e97\u2013e103 (2009).","journal-title":"International journal of medical informatics"},{"key":"5552_CR61","unstructured":"Pathak, J. et al. In AMIA Annual Symposium Proceedings. 1089 (American Medical Informatics Association)."},{"key":"5552_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0333102413499649","volume":"34","author":"G Roberto","year":"2014","unstructured":"Roberto, G., Piccinni, C., D\u2019Alessandro, R. & Poluzzi, E. Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia 34, 5\u201313, doi:10.1177\/0333102413499649 (2014).","journal-title":"Cephalalgia"},{"key":"5552_CR63","doi-asserted-by":"publisher","first-page":"E97","DOI":"10.1016\/j.ijmedinf.2009.01.001","volume":"78","author":"RK Pearson","year":"2009","unstructured":"Pearson, R. K. et al. Influence of the MedDRA (R) hierarchy on pharmacovigilance data mining results. International Journal of Medical Informatics 78, E97\u2013E103, doi:10.1016\/j.ijmedinf.2009.01.001 (2009).","journal-title":"International Journal of Medical Informatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05552-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:27:00Z","timestamp":1750541220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05552-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["5552"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-05552-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]},"assertion":[{"value":"4 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5527"}}